1. Pantaleo G, Graziosi C, Fauci AS. 1993. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-35

2. Sellmeyer DE, Grunfeld C. 1996. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 17: 518-32

3. Chrousos GP. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351-62

4. Andrieu JM, Lu W, Levy R. 1995. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 171: 523-30

5. Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorrilla C, Vajaranant M, Dobles AR, Jones TB, Carlan S, Allen DY. 2000. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 25: 306-11

6. Tashima KT, Flanigan TP. 2000. Antiretroviral therapy in the year 2000. Infect Dis Clin North Am 14: 827-49

7. Vella S, Palmisano L. 2000. Antiretroviral therapy: state of the HAART. Antiviral Res 45: 1-7

8. Harrington M, Carpenter CC. 2000. Hit HIV-1 hard, but only when necessary. Lancet 355: 2147-52

9. Kaufmann GR, Cooper DA. 2000. Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr Opin Microbiol 3: 508-14

10. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 1998. "Buffalo hump" in men with HIV-1 infection. Lancet 351: 867-70

11. Chrousos GP, Detera-Wadleigh SD, Karl M. 1993. Syndromes of glucocorticoid resistance. Ann Intern Med 119: 1113-24

12. Bamberger CM, Schulte HM, Chrousos GP. 1996. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17: 245-61

13. Clark JK, Schrader WT, O'Malley BW. 1992. Mechanism of steroid hormones. In Williams Textbook of Endocrinology, ed. JD Wilson, DW Foster, pp. 35-90. Philadelphia: WB Sanders Co.

14. Munck A, Guyre PM, Holbrook NJ. 1984. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5: 25-44

15. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. 1993. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1198-208

16. Chrousos GP, Kino T. 2005. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005: pe48

17. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. 1995. Glucocorticoid receptor b, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95: 2435-41

18. Kino T. 2007. Tissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoids. Horm Metab Res 39: 420-4

19. Vottero A, Chrousos GP. 1999. Glucocorticoid Receptor b: View I. Trends Endocrinol Metab 10: 333-8

20. Lonard DM, Lanz RB, O'Malley BW. 2007. Nuclear receptor coregulators and human disease. Endocr Rev 28: 575-87

21. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. 1996. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319-24

22. McKenna NJ, Lanz RB, O'Malley BW. 1999. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321-44

23. Heery DM, Kalkhoven E, Hoare S, Parker MG. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-6

24. Chrousos GP, Kino T. 2007. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10: 213-9

25. Charmandari E, Kino T. 2007. Novel causes of generalized glucocorticoid resistance. Horm Metab Res 39: 445-50

26. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. 2003. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol 85: 457-67

27. Kino T, Chrousos GP. 2001. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J Endocrinol 169: 437-45

28. Bricaire F, Marche C, Zoubi D, Regnier B, Saimot AG. 1988. Adrenocortical lesions and AIDS. Lancet 1: 881

29. Glasgow BJ, Steinsapir KD, Anders K, Layfield LJ. 1985. Adrenal pathology in the acquired immune deficiency syndrome. Am J Clin Pathol 84: 594-7

30. Guarda LA, Luna MA, Smith JL, Jr., Mansell PW, Gyorkey F, Roca AN. 1984. Acquired immune deficiency syndrome: postmortem findings. Am J Clin Pathol 81: 549-57

31. Hawken MP, Ojoo JC, Morris JS, Kariuki EW, Githui WA, Juma ES, Gathua SN, Kimari JN, Thiong'o LN, Raynes JG, Broadbent P, Gilks CF, Otieno LS, McAdam KP. 1996. No increased prevalence of adrenocortical insufficiency in human immunodeficiency virus-associated tuberculosis. Tuber Lung Dis 77: 444-8

32. Seel K, Guschmann M, van Landeghem F, Grosch-Worner I. 2000. Addison-disease - an unusual clinical manifestation of CMV-end organ disease in pediatric AIDS. Eur J Med Res 5: 247-50

33. Angulo JC, Lopez JI, Flores N. 1994. Lethal cytomegalovirus adrenalitis in a case of AIDS. Scand J Urol Nephrol 28: 105-6

34. Greene LW, Cole W, Greene JB, Levy B, Louie E, Raphael B, Waitkevicz J, Blum M. 1984. Adrenal insufficiency as a complication of the acquired immunodeficiency syndrome. Ann Intern Med 101: 497-8

35. Hoshino Y, Yamashita N, Nakamura T, Iwamoto A. 2002. Prospective examination of adrenocortical function in advanced AIDS patients. Endocr J 49: 641-7

36. Verges B, Chavanet P, Desgres J, Vaillant G, Waldner A, Brun JM, Putelat R. 1989. Adrenal function in HIV infected patients. Acta Endocrinol (Copenh) 121: 633-7

37. Biglino A, Limone P, Forno B, Pollono A, Cariti G, Molinatti GM, Gioannini P. 1995. Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol 133: 173-9

38. Lortholary O, Christeff N, Casassus P, Thobie N, Veyssier P, Trogoff B, Torri O, Brauner M, Nunez EA, Guillevin L. 1996. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab 81: 791-6

39. Coodley GO, Loveless MO, Nelson HD, Coodley MK. 1994. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr 7: 46-51

40. Findling JW, Buggy BP, Gilson IH, Brummitt CF, Bernstein BM, Raff H. 1994. Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus. J Clin Endocrinol Metab 79: 1091-6

41. Kumar M, Kumar AM, Morgan R, Szapocznik J, Eisdorfer C. 1993. Abnormal pituitary-adrenocortical response in early HIV-1 infection. J Acquir Immune Defic Syndr 6: 61-5

42. Malone JL, Oldfield ECd, Wagner KF, Simms TE, Daly R, O'Brian J, Burke DS. 1992. Abnormalities of morning serum cortisol levels and circadian rhythms of CD4+ lymphocyte counts in human immunodeficiency virus type 1-infected adult patients. J Infect Dis 165: 185-6

43. Christeff N, Gherbi N, Mammes O, Dalle MT, Gharakhanian S, Lortholary O, Melchior JC, Nunez EA. 1997. Serum cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology 22: S11-8

44. de la Torre B, von Krogh G, Svensson M, Holmberg V. 1997. Blood cortisol and dehydroepiandrosterone sulphate (DHEAS) levels and CD4 T cell counts in HIV infection. Clin Exp Rheumatol 15: 87-90

45. Stolarczyk R, Rubio SI, Smolyar D, Young IS, Poretsky L. 1998. Twenty-four-hour urinary free cortisol in patients with acquired immunodeficiency syndrome. Metabolism 47: 690-4

46. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. 1988. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 84: 611-6

47. Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. 1991. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 5: 729-33

48. Malaty LI, Kuper JJ. 1999. Drug interactions of HIV protease inhibitors. Drug Saf 20: 147-69

49. Rouanet I, Peyriere H, Mauboussin JM, Vincent D. 2003. Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone. HIV Med 4: 149-50

50. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. 1999. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 75: 274

51. Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. 1999. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone. Aids 13: 1803

52. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M. 2000. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 14: 499-507

53. Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Holmberg SD, Palella FJ. 2004. Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort. AIDS Patient Care STDS 18: 721-7

54. Brook MG, Dale A, Tomlinson D, Waterworth C, Daniels D, Forster G. 2001. Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units. AIDS Patient Care STDS 15: 491-4

55. Stocker DN, Meier PJ, Stoller R, Fattinger KE. 1998. "Buffalo hump" in HIV-1 infection. Lancet 352: 320-1

56. Brinkman K, Smeitink JA, Romijn JA, Reiss P. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-5

57. Gkrania-Klotsas E, Klotsas AE. 2007. HIV and HIV treatment: effects on fats, glucose and lipids. Br Med Bull 84: 49-68

58. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. 2006. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review. Dig Liver Dis 38: 363-73

59. Dakin CL, O'Connor CA, Patsdaughter CA. 2006. HAART to heart: HIV-related cardiomyopathy and other cardiovascular complications. AACN Clin Issues 17: 18-29

60. Nanavati KA, Fisher SD, Miller TL, Lipshultz SE. 2004. HIV-related cardiovascular disease and drug interactions. Am J Cardiovasc Drugs 4: 315-24

61. Richman DD. 2001. HIV chemotherapy. Nature 410: 995-1001

62. Correll T, Klibanov OM. 2008. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 28: 90-101

63. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4: 72-7

64. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698-703

65. Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT, Jr., Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. 2003. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis 188: 531-6

66. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, Pantaleo G. 2002. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 109: 681-8

67. Andrieu JM, Lu W. 2004. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2: 17

68. McComsey GA, Whalen CC, Mawhorter SD, Asaad R, Valdez H, Patki AH, Klaumunzner J, Gopalakrishna KV, Calabrese LH, Lederman MM. 2001. Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 15: 321-7

69. Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM. 2003. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr 32: 281-6

70. Dichter JR, Lundgren JD, Nielsen TL, Jensen BN, Schattenkerk J, Benfield TL, Lawrence M, Shelhamer J. 1999. Pneumocystis carinii pneumonia in HIV-infected patients: effect of steroid therapy on surfactant level. Respir Med 93: 373-8

71. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ. 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351: 1741-51

72. Aster RH. 1994. Thrombocytopenia in the HIV-infected patient. Hosp Pract (Off Ed) 29: 81-6

73. Koduri PR, Singa P, Nikolinakos P. 2002. Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1. Am J Hematol 70: 174-6

74. Levy R, Colonna P, Tourani JM, Gastaut JA, Brice P, Raphael M, Taillan B, Andrieu JM. 1995. Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Leuk Lymphoma 16: 451-6

75. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. 2006. Counteracting muscle wasting in HIV-infected individuals. HIV Med 7: 299-310

76. Belec L, Meillet D, Hernvann A, Gresenguet G, Gherardi R. 1994. Differential elevation of circulating interleukin-1b, tumor necrosis factor a, and interleukin-6 in AIDS-associated cachectic states. Clin Diagn Lab Immunol 1: 117-20

77. Osborn L, Kunkel S, Nabel GJ. 1989. Tumor necrosis factor a and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kB. Proc Natl Acad Sci U S A 86: 2336-40

78. Ansari AW, Schmidt RE, Heiken H. 2007. Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings. Clin Immunol 125: 1-4

79. Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, Hoffmann MK, Horowitz HW. 2001. Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons. J Infect Dis 184: 1328-30

80. Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG, Mican JM, Liu S, Gerber LH, Blackwelder WC, Falloon J, Davey RT, Polis MA, Walker RE, Lane HC, Kovacs JA. 2002. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 137: 17-25

81. Scribner AN, Troia-Cancio PV, Cox BA, Marcantonio D, Hamid F, Keiser P, Levi M, Allen B, Murphy K, Jones RE, Skiest DJ. 2000. Osteonecrosis in HIV: a case-control study. J Acquir Immune Defic Syndr 25: 19-25

82. Glesby MJ, Hoover DR, Vaamonde CM. 2001. Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study. J Infect Dis 184: 519-23

83. Panayotakopoulos GD, Day S, Peters BS, Kulasegaram R. 2006. Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines. Int J STD AIDS 17: 567-8

84. Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, Ducar C, Ellner JJ, Whitworth JA, Mugerwa R, Johnson JL, Okwera A. 2004. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 190: 869-78

85. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN. 2003. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 17: 860-9

86. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K. 2004. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101: 227-32

87. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G. 2005. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A 102: 15827-32

88. Norbiato G, Bevilacqua M, Vago T, Baldi G, Chebat E, Bertora P, Moroni M, Galli M, Oldenburg N. 1992. Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 608-13

89. Vagnucci AH, Winkelstein A. 1993. Circadian rhythm of lymphocytes and their glucocorticoid receptors in HIV-infected homosexual men. J Acquir Immune Defic Syndr 6: 1238-47

90. Norbiato G, Bevilacqua M, Vago T, Baldi G, Castellia L, Righini V. 1994. Glucocorticoid resistance in the acquired immunodeficiency syndrome. Effects on the immunosystem. Presented at The 76th Annual Meeting of The Endocrine Society, Anaheim. CA

91. Sher ER, Leung DY, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ. 1994. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93: 33-9

92. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. 1993. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 151: 3460-6

93. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q. 1995. Dysregulation of interleukin 4, interleukin 5, and interferon g gene expression in steroid-resistant asthma. J Exp Med 181: 33-40

94. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ. 1997. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor b. J Exp Med 186: 1567-74

95. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. 1999. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 13: 2251-60

96. Saint-Marc T, Touraine JL. 1998. "Buffalo hump" in HIV-1 infection. Lancet 352: 319-20

97. De Luca A, Murri R, Damiano F, Ammassari A, Antinori A. 1998. "Buffalo hump" in HIV-1 infection. Lancet 352: 320

98. Darvay A, Acland K, Lynn W, Russell-Jones R. 1999. Striae formation in two HIV-positive persons receiving protease inhibitors. J Am Acad Dermatol 41: 467-9

99. Dornier C, Posth M, Granel F, Barbaud A, Schmutz JL. 1999. "Buffalo hump" related to indinavir treatment. Ann Dermatol Venereol 126: 720-2

100. Chrousos GP. 2000. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 24 Suppl 2: S50-5

101. Kino T, Chrousos GP. 2007. Virus-mediated modulation of the host endocrine signaling systems: clinical implications. Trends Endocrinol Metab 18: 159-66

102. Kino T, Mirani M, Alesci S, Chrousos GP. 2003. AIDS-related lipodystrophy/insulin resistance syndrome. Horm Metab Res 35: 129-36

103. Carr A, Samaras K, Chisholm DJ, Cooper DA. 1998. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-3

104. Lenhard JM, Weiel JE, Paulik MA, Furfine ES. 2000. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. Biochem Pharmacol 59: 1063-8

105. Murata H, Hruz PW, Mueckler M. 2000. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275: 20251-4

106. Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA, Weiel JE. 2000. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 47: 121-9

107. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. 1999. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 84: 4274-7

108. Jiminez-Exposito MJ, Paul A, Laville A, Masana L. 1997. Non-activity of hepatic lipase during a treatment with ritonavir. Presented at Proceedings of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamberg, Germany

109. Behrens GM, Stoll M, Schmidt RE. 2000. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 23: 57-76

110. Chrousos GP. 2000. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol 106: S275-91

111. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO, Grinspoon SK. 1998. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 27: 68-72

112. Pavlakis GN. 1996. The molecular biology of HIV-1. In AIDS: Diagnosis, Treatment and Prevention, ed. VT DeVita, S Hellman, SA Rosenberg, pp. 45-74. Philadelphia: Lippincott Raven

113. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, Falloon J. 1999. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 84: 1925-31

114. Norbiato G, Bevilacqua M, Vago T, Clerici M. 1997. Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Clin Exp Rheumatol 15: 315-3123

115. Norbiato G, Bevilacqua M, Vago T, Clerici M. 1996. Glucocorticoids and interferon-a in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 81: 2601-6

116. Elenkov IJ, Chrousos GP. 1999. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab 10: 359-68

117. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. 1999. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 84: 1932-7

118. Belec L, Mhiri C, DiCostanzo B, Gherardi R. 1992. The HIV wasting syndrome. Muscle Nerve 15: 856-7

119. Simpson DM, Bender AN. 1988. Human immunodeficiency virus-associated myopathy: analysis of 11 patients. Ann Neurol 24: 79-84

120. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP. 1999. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189: 51-62

121. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. 2002. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 169: 6361-8

122. Fakruddin JM, Laurence J. 2005. HIV-1 Vpr enhances production of receptor of activated NF-kB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 150: 67-78

123. Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN. 2002. Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76: 9724-34

124. Kino T, Pavlakis GN. 2004. Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol 23: 193-205

125. Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553-77

126. Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, Chrousos GP, Kopp JB. 2007. HIV-1 Vpr suppresses transcriptional activity of PPARg and inhibits adipocyte differentiation: Implications for HIV-associated lipodystrophy. Mol Endocrinol in press

127. Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC. 2002. HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 302: 95-105

128. Kino T, Slobodskaya O, Pavlakis GN, Chrousos GP. 2002. Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex. J Biol Chem 277: 2396-405

129. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. 1994. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 91: 664-8

130. Kino T, Gragerov A, Valentin A, Tsopanomihalou M, Ilyina-Gragerova G, Erwin-Cohen R, Chrousos GP, Pavlakis GN. 2005. Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 79: 2780-7

131. Kino T, De Martino MU, Charmandari E, Ichijo T, Outas T, Chrousos GP. 2005. HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54: 23-31

132. Barthel A, Schmoll D, Unterman TG. 2005. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 16: 183-9

133. Kino T, Chrousos GP. 2004. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome? Ann N Y Acad Sci 1024: 153-67

134. Baumann CA, Chokshi N, Saltiel AR, Ribon V. 2000. Cloning and characterization of a functional peroxisome proliferator activator receptor-g-responsive element in the promoter of the CAP gene. J Biol Chem 275: 9131-5